Figure 1.

Treatment of human VSMCs with PGF2α, ACh, and 5-HT increases the phosphorylated level of MLC2. Human VSMCs were treated with serial doses of PGF2α2α (A, B), ACh (C, D), and 5-HT (E, F). The p-MLC2 level was detected by Western blotting. Under constant doses of vasoconstrictors, VSMCs were treated with PGF2α (B, dose=30 μM/ml), ACh (D, dose=0.5 μM/ml), and 5-HT (F, dose=3 μM/ml) in incremental time periods, as indicated. The lower bars in each panel are relative p-MLC2 levels after normalization to GAPDH. Data were obtained from 3 independent experiments with each in triplicate. * p<0.05 vs. control (without any reagent treatment in A, C and E, or at the beginning of treatment in B, D, and F) by t-test.